Ovarian function preservation with GnRH agonist in young breast cancer patients: Does it impede the effect of adjuvant chemotherapy?
Open Access
- 1 October 2014
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 23 (5) , 670-675
Abstract
No abstract availableKeywords
Funding Information
- Korea Healthcare Technology R&D Project
- Ministry for Health & Welfare Affairs, Republic of Korea (A092255)
- Samsung Biomedical Research Institute
This publication has 35 references indexed in Scilit:
- Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast CancerNew England Journal of Medicine, 2010
- Depressive symptoms among young breast cancer survivors: the importance of reproductive concernsBreast Cancer Research and Treatment, 2010
- Breast Cancer Before Age 40 YearsSeminars in Oncology, 2009
- Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene ExpressionJournal of Clinical Oncology, 2008
- Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast CancerJournal of Clinical Oncology, 2006
- Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective StudyJournal of Clinical Oncology, 2006
- Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5Journal of Clinical Oncology, 2005
- Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot studyAnti-Cancer Drugs, 2002
- Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?The Lancet, 2000
- Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patientsEuropean Journal of Cancer, 2000